Literature DB >> 3944473

Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes.

S Tanaka, T Suzuki, K Nishioka.   

Abstract

Methods for measurement of classical complement pathway activity (CH50) and alternative complement pathway activity (ACH50) in mouse serum using rabbit erythrocytes sensitized with guinea pig anti-rabbit erythrocyte antibody have been established. The assays measured CH50 values in mouse sera that could hardly be determined by the conventional method using antibody-sensitized sheep red blood cells. Mouse serum ACH50 values determined by the method were also 5-7 times higher than those obtained in conventional assays with rabbit erythrocytes. Both the CH50 and ACH50 values varied with the strain among the 25 different strains of mice studied. BALB/c (nu/nu, male), LT/SuJ and Jcl-ICR27 strains exhibited higher CH50 values, and NIH (nu/+), ICR (nu/nu), NOD (male) and AKR strains showed lower values. The ACH50 was higher in C3H/HeN (male), C57BL/6J (male), Jcl-ICR27 and BALB/c (nu/nu, male) mice, and lower in ICR (nu/nu), NOD (female) and AKR mice. Sera from 16 out of the 25 mouse strains showed ACH50 values comparable to or higher than those in man. As for CH50, however, even the highest value seen in BALB/c (nu/nu, male) mice corresponded to about three-fifths of an average value in man. It is concluded that the complement system of mice, especially the alternative pathway of complement activation, functions as actively as that in man. It was also found that male mice have higher CH50 and ACH50 values than female mice. The differences in these parameters between males and females were only slight at the age of 4 weeks and became conspicuous after 6 weeks at which time both the CH50 and ACH50 virtually reached their respective peak levels of activity.

Entities:  

Mesh:

Year:  1986        PMID: 3944473     DOI: 10.1016/0022-1759(86)90448-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.

Authors:  Kristen N Delaney; James P Phipps; John B Johnson; Steven B Mizel
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

2.  Immunological and nonimmunological control of severity of Trypanosoma musculi infections in C3H and C57BL/6 inbred mice.

Authors:  J W Albright; J F Albright
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

3.  Cooperative action of complement component C3 and phagocytic effector cells in innate murine resistance to Trypanosoma lewisi.

Authors:  B B Desai; J W Albright; J F Albright
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

4.  Gene responsible for deficient activity of the beta subunit of C8, the eighth component of complement, is located on mouse chromosome 4.

Authors:  S Tanaka; T Suzuki; M Sakaizumi; Y Harada; Y Matsushima; N Miyashita; Y Fukumori; S Inai; K Moriwaki; H Yonekawa
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

5.  CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism.

Authors:  Ruth D Lewis; Mark J Perry; Irina A Guschina; Christopher L Jackson; B Paul Morgan; Timothy R Hughes
Journal:  Am J Pathol       Date:  2011-08-02       Impact factor: 4.307

6.  Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice.

Authors:  Anja C Bloom; Fraser L Collins; Rob J Van't Hof; Elizabeth S Ryan; Emma Jones; Timothy R Hughes; B Paul Morgan; Malin Erlandsson; Maria Bokarewa; Daniel Aeschlimann; Bronwen A J Evans; Anwen S Williams
Journal:  Bone       Date:  2015-12-22       Impact factor: 4.398

7.  Pathogenesis of arteritis of SL/Ni mice. Possible lytic effect of anti-gp70 antibodies on vascular smooth muscle cells.

Authors:  M Miyazawa; M Nose; M Kawashima; M Kyogoku
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

Review 8.  Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential.

Authors:  Julia A Sharp; Pamela H Whitley; Kenji M Cunnion; Neel K Krishna
Journal:  Front Immunol       Date:  2014-08-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.